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Reducing return of disease activity in patients with
relapsing multiple sclerosis transitioned from
natalizumab to teriflunomide: 12-month interim
results of teriflunomide therapy
Stanley L Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O’Connor,
Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen , James Thomas, Kyle Smoot,
Kiren Kresa-Reahl , Kateri J Spinelli
Abstract
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease
activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.
Objective: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing
multiple sclerosis patients.
Methods: Clinically stable relapsing multiple sclerosis patients completing 12 or more consecutive
months of natalizumab, testing positive for anti-John Cunningham virus antibody, started teriflunomide
14 mg/day, 28 7 days after their final natalizumab infusion. Physical examination, Expanded
Disability Status Scale, laboratory assessments, and brain magnetic resonance imaging were performed
at screening and multiple follow-up visits.
Results: Fifty-five patients were enrolled in the study. The proportion of patients relapse-free was 0.94,
restricted mean time to first gadolinium-enhancing lesion was 10.9 months and time to 3-month sus-
tained disability worsening was 11.8 months. The mean number of new or enlarging T2 lesions per
patient at 12 months was 0.42. Exploratory analyses revealed an annualized relapse rate of 0.08, and a
proportion of patients with no evidence of disease activity of 0.68. Forty-seven patients (85.5%) reported
adverse events, 95% of which were mild to moderate.
Conclusions: Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of
return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clin-
ically stable patients off natalizumab to another therapy.
ClinicalTrials.gov Identifier: NCT01970410
Keywords: Relapsing multiple sclerosis, natalizumab, teriflunomide, disease recurrence, anti-JC virus
antibodies, switch strategy
Date received: 20 June 2018; Revised received 14 December 2018; accepted: 17 December 2018
Introduction
Cell-mediated inflammation is a hallmark of multi-
ple sclerosis (MS) that contributes to neurological
impairment and has prompted the development of
disease-modifying therapies (DMTs) that destroy,
suppress, or alter the pro-inflammatory behavior of
cells, primarily lymphocytes and monocytes.
Natalizumab, an effective monoclonal antibody ther-
apy for relapsing multiple sclerosis (RMS),1 inhibits
migration of these cells into the central nervous
system (CNS),2 but increases the risk of developing
progressive multifocal leukoencephalopathy (PML)
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in patients infected by John Cunningham virus
(JCV).3 Evidence of JCV exposure is found in
more than 50% of the adult MS population.4 PML
risk in JCV-infected patients increases with the dura-
tion of natalizumab use, rates approximating 3/1000
for 2–4 years’ use, 6/1000 for 4–6 years’ use, and
12–13/1000 for patients who had also been treated
with cytotoxic or immunosuppressant chemothera-
peutic agents.5
PML risk has prompted the discontinuation of nata-
lizumab in a large percentage of patients. However,
studies have reported heightened MS disease activity
after natalizumab withdrawal, including increased
relapse frequency,6–14 increased disease activity on
magnetic resonance imaging (MRI),8–10,14,15
increased relapse severity,6,7 and relapse-related
fatalities.12,13 Several studies have not substantiated
these observations.15–17 To date there are few data
on successful therapeutic strategies to transition
patients off natalizumab while reducing the risk of
disease reactivation.
The post-natalizumab use of glatiramer acetate,
interferon beta or methylprednisolone was not ben-
eficial for patients.8 In a post-hoc, cross-sectional
analysis, initiating dimethyl fumarate sooner than
90 days after the last natalizumab dose was associ-
ated with a lower risk of relapse.18 In a retrospective
study of patients switching to fingolimod, 61% of
patients experienced relapse after discontinuing
natalizumab, 48% of whom relapsed while receiving
fingolimod, mostly occurring after 13–24 weeks
of natalizumab washout.7 In a prospective study of
patients switching from natalizumab to fingolimod,
11.5% of patients relapsed within 6 months.10 The
odds ratio of relapse was 7.2 for patients with wash-
out of 8–12 weeks versus those with 4 or fewer
weeks’ washout. A placebo controlled prospective
study of fingolimod demonstrated a 9–12% and
16% relapse risk with natalizumab washout of
up to 12 and 16 weeks, respectively, but a 61%
relapse risk after a 3-month natalizumab washout.19
Evidence of reduced disease activity on MRI
was observed with fingolimod initiation within
8–12 weeks of stopping natalizumab.15 These
studies suggest that a longer duration of post-
natalizumab washout increases the risk of resumed
disease activity. In comparing fingolimod to rituxi-
mab, only 1.8% of rituximab-treated patients had a
relapse, compared to 17.6% of fingolimod-treated
patients, with no significant effect of differing nata-
lizumab washout duration.20
This study examined teriflunomide as replacement
therapy for clinically stable RMS patients taken
off natalizumab because of prior JCV exposure.
Teriflunomide, an approved medication for RMS
treatment that inhibits de-novo pyrimidine synthesis
by blocking mitochondrial dihydroorotate dehydro-
genase, was selected because of its acceptable
safety profile.21,22 Higher efficacy medications
such as alemtuzumab and ocrelizumab were not
yet approved when this study began.
Materials and methods
Study design
This is a prospective, observational cohort study
conducted at three US community-based MS clinics.
Data from study initiation (July 2013) until the
final patient completed month 12 (31 August 2017)
are included. Eligibility criteria included age of
21–60 years, diagnosis of RMS, being relapse free
for 12 months prior to screening visit, baseline
Expanded Disability Status Scale (EDSS) between
1.0 and 6.0, no evidence of significant cognitive lim-
itation or psychiatric disorder, stable brain MRIs in
the 12 months prior to the screening visit, defined as
no new or enlarged T2 or gadolinium-enhancing
lesions, receiving at least 12 consecutive months of
natalizumab treatment, and a positive serum anti-
JCV IgG titer. After providing informed consent
and completing study screening, patients started
oral teriflunomide, 14 mg a day 28 7 days after
their last natalizumab infusion.
Physical examination, EDSS, adverse event (AE)
and laboratory assessments, and concomitant medi-
cation review were performed at screening and base-
line visits, monthly for 6 months, then at 9 and
12 months. Brain MRI was completed at screening,
monthly for 6 months, and at 12 months. Symbol
digit modality test (SDMT) and Beck depression
inventory-II (BDI-II) were completed at baseline,
6 months and 12 months.
Patients at each site were studied on the same 3T
scanner throughout the study. MRI sequences
included axial and sagittal T2 fluid-attenuated inver-
sion recovery (FLAIR), axial T1, axial T2, axial
diffusion-weighted images, and axial spin-echo T1
following gadobutrol 0.1 mmol/kg administration.
Axial and sagittal T2 FLAIR three-dimensional
(3D) images were contiguous non-gapped 1 mm
thick sections. Other images were contiguous non-
gapped, 3 mm thick. Gadolinium T1 images were
obtained after a 10-minute post-infusion delay,
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with 1 mm 3D T1 magnetization prepared rapid
acquisiton gradient echo (MPRAGE) sequences
and 3 mm axial spin-echo T1-weighted sequences.
Scans were reviewed by neuroradiologists with
extensive experience in MRI MS assessment.
Study AEs were reported according to International
Conference of Harmonization guidelines. Study
approval was obtained from each site’s institutional
review board (IRB), and written informed consent
was obtained from all participating patients.
Continuing review for safety was performed by the
IRBs throughout the study.
Trial endpoints
The primary study endpoint was the proportion of
relapse-free patients at 12 months. Secondary end-
points included time to first gadolinium-enhancing
lesion, time to 3-month sustained disability worsen-
ing (SDW), and the number of new or enlarging
T2-weighted lesions. Non-pre-specified exploratory
endpoints at 12 months included annualized relapse
rate (ARR), mean number of gadolinium-enhancing
lesions, the proportion of patients with no new or
enlarged T2 lesions, no gadolinium-enhancing
lesions, no evidence of SDW, and no evidence of
disease activity (NEDA-3), defined as no occurrence
of clinical relapses, SDW, gadolinium-enhancing, or
new or enlarging T2 lesions. Changes in SDMT and
BDI-II from baseline to 6 and 12 months were also
examined (see Supplementary Figure 1).
A relapse was defined as new or worsened neurolog-
ical symptoms, unassociated with fever or evidence
of infection, lasting at least 24 hours, and an increase
of 1 or more points in two or more functional scales,
or 2 or more points in one functional scale. All
patients reporting suspected relapse symptoms
were evaluated within 7 days of onset by their
study treating neurologist. All relapses were con-
firmed by the principal investigators (KE and
SLC). SDW was defined as an increase of 1.5 or
more points for patients with a baseline EDSS of
0, 1 or more points for patients with EDSS of 1–5,
and 0.5 or more points for patients with EDSS of
5.5–6.0, sustained for 3 months. Patients with a 1 or
more point increase in EDSS in whom a second
measure was not obtained 3 months later were not
included as SDW.
Statistical analysis
Analysis was based on an intention-to-treat model
and included all enrolled patients who received at
least one dose of teriflunomide. Patient characteris-
tics were summarized as percentages, means (SD) or
medians (interquartile range), as appropriate.
Kaplan–Meier analysis was used to estimate the pro-
portion of patients relapse free at 12 months. For
secondary endpoints, restricted mean time to- first
gadolinium-enhancing lesion and time to SDW were
calculated as the area under the Kaplan–Meier curve
up to12 months and interpreted as the number of
months, out of 12, a patient would be event free.23
The mean number of new or enlarging T2 lesions at
12 months was calculated using negative binomial
regression, with the number of lesions as the depen-
dent variable and the natural logarithm of follow-up
time as an offset.
In exploratory analyses, negative binomial regres-
sion was used to estimate the ARR and mean
number of gadolinium-enhancing lesions at
12 months, with the number of events as the depen-
dent variable and the natural logarithm of follow-up
time as an offset. Kaplan–Meier analyses were used
to estimate the proportion of patients with no new or
enlarging T2 lesions, no gadolinium-enhancing
lesions, no SDW at 12 months, and NEDA-3. Log
rank tests were used to compare survival curves by
the following subgroups: gender, age (<50 vs.
50 years), disease duration (<15 vs. 15 years),
duration of natalizumab treatment (<2 vs. 2 years),
baseline EDSS (<3 vs. 3 years), and the number of
relapses in the year prior to starting natalizumab
(0 vs. 1). Subgroup analyses were not pre-
specified for this exploratory analysis, and no post-
hoc adjustments for multiple comparisons were used.
Linear mixed-effects models (LMMs) were used to
analyze the change in SDMT and BDI-II from base-
line to months 6 and 12. Each model included time
as a categorical fixed effect, patient as a random
intercept, and an unstructured variance–covariance
matrix. LMMs provide unbiased estimates in the
presence of missing data under the assumption that
the model is correctly specified and data are missing
at random. Scatter plots of residuals were examined
to assess lack of fit. Least squares means with stan-
dard errors and changes with 95% confidence inter-
vals and P values were reported.24 R packages
MASS, survival, survminer, lme4, lmerTest, and
ggplot2 were used for analyses and figures.
Results
Sixty-two patients were screened and 55 patients
completed the baseline visit. Reasons for not com-
pleting the baseline visit included wanting to
become pregnant (one), and as per protocol eligibil-
ity criteria, enhancing MRI lesions at screening
Cohan et al.
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(four), negative JCV status (one), and severe depres-
sion at screening (one) (Figure 1). Of 55 patients
completing the baseline visit, 49 (89.1%) completed
12 months of study. Two patients from site 1 with-
drew at month 4 due to MRI progression (one) and
severe diarrhea (one). All four patients from site 3
had no verifiable clinical or MRI data past the date
of the site coordinator’s unexpected death, however
their clinical, safety, and imaging data were included
in the analyses up to the date of the coordinator’s
death (follow-up of 2 months for two patients and
4 months for two patients), during which no relapses,
MRI changes, or AEs were reported. Four of the 49
patients completing 12 months of study discontinued
teriflunomide before 12 months: one at month 5 due
to relapse, one at month 5 due to MRI worsening,
and two at months 9 and 11 due to AEs (Figure 1).
Of the 55 enrolled patients, 53 (96.4%) were white
and two (3.6%) were African American, 42 (76.4%)
were women, and the mean age was 47.2 years
(10.1, range 19–64 years) (Table 1). By
12 months, two patients had experienced one clinical
relapse (months 3 and 5), and one patient had two
clinical relapses (months 6 and 9) resulting in a
relapse-free proportion of 0.94 (95% confidence
interval (CI) 0.83, 0.98) (Table 2). Secondary end-
points included a restricted mean time to first
gadolinium-enhancing lesion of 10.9 months (95%
CI 10.1, 11.7), with first gadolinium-enhancing
Figure 1. Patient attrition diagram. TFM: teriflunomide.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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lesions found for 11 patients: three at month 3, one
at month 4, four at month 6, and three at month 12.
Two patients had SDW (months 4 and 9), resulting
in a restricted mean time to SDW of 11.8 months
(95% CI 11.4, 12.0). Thirteen patients had at least
one new or enlarging T2 lesion: one at month 2,
three at month 3, one at month 4, two at month 5,
three at month 6, and nine at month 12, resulting in a
mean number of new or enlarging T2 lesions per
patient at 12 months of 0.42 (95% CI 0.23, 0.77)
(Table 2).
Exploratory endpoints included an ARR of
0.08 (95% CI 0.02, 0.26) and a mean number
of gadolinium-enhancing lesions per patient at
12 months of 0.34 (95% CI 0.18, 0.63). The
12-month new or enlarging T2 lesion-free proportion
was 0.74 (95% CI 0.60, 0.84), the gadolinium-
enhancing lesion-free proportion was 0.78 (95%
CI 0.64, 0.87), and the SDW-free proportion was
0.96 (95% CI 0.85, 0.99). NEDA-3 was achieved
in 39 patients by 12 months, resulting in a disease
activity-free proportion of 0.68 (95% CI 0.53, 0.79)
(Table 2; Figure 2). Patients with disease duration of
less than 15 years were more likely to have
gadolinium-enhancing lesions than those with 15
or more years (gadolinium-enhancing lesion-free
proportion at 12 months 0.58 vs. 0.88; log rank
P=0.011) (Figure 2). No other significant differences
in survival curves were found for gender, age, dis-
ease duration, duration of prior natalizumab treat-
ment, baseline EDSS, or the number of relapses in
the year prior to starting natalizumab. There were
no significant changes in SDMT or BDI-II from
baseline to 6 or 12 months (Table 2).
Forty-seven patients (85.5%) reported AEs, of
which 95% were mild to moderate and 5% were
severe (see Supplementary Table 1). Serious, most
commonly reported (five or more occurrences), and
AEs causing teriflunomide withdrawal are presented
in Table 3. There were 10 serious AEs reported in
five patients, six of which occurred in the same
patient: Staphylococcus aureus empyema, pleural
effusion, pneumothorax and secondary brain abscess
with subfalcial herniation, and obstructive hydro-
cephalus. This patient at no time had leukopenia,
but had absolute lymphocyte counts of 0.7 109/L
before, and 0.3–1.1 109/L during and after resolu-
tion of the AEs (reference range 1.0–4.8 109/L). In
the remaining four patients, there was one case each
of ruptured gangrenous appendicitis, pneumonia,
pyelonephritis, and localized squamous cell carcino-
ma (Table 3). All five patients recovered.
The top five most reported AEs included hair thin-
ning or loss (36.4%), diarrhea or loose stool
(30.9%), headache (21.8%), nausea/vomiting
Table 1. Demographic and disease characteristics of patients at baseline.
Characteristic Value
Number of patients 55
Age in years, mean (SD); range 47.2 (10.1); 19–64a
Women, % (n) 76.4 (42)
Race, % (n)
African American 3.6 (2)
White 96.4 (53)
Disease duration in years, mean (SD) 18.6 (8.4)
Years of formal education, median (IQR) 14 (12, 16)
Working at baseline, % (n) 58.2 (32)
Duration of prior natalizumab in years, median (IQR) 2.8 (1.5, 5.3)
ARR in year prior to natalizumab start 1.53
No relapses in year prior to natalizumab start, % (n) 23.6 (13)
EDSS at baseline, mean (SD); median (IQR) 3.0 (1.4); 2.5 (2.0, 3.8)
SDMT at baseline, mean (SD) 51.8 (11.3)
BDI-II at baseline, median (IQR) 5.0 (2.5, 11.0)
aWaivers were obtained to include one 19-year-old, one 62-year-old, two 63-year-olds, and one 64-year-old who did
not meet inclusion criteria for age range of 21–60 years.
IQR: interquartile range; ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale; SDMT: symbol digit
modalities test; BDI-II: Beck depression inventory-II.
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Table 2. Clinical endpoints during 12-month study (intention-to-treat population).
No. of patients 55
By month 6 By month 12
Primary endpoint
Patients relapse-free, 52
Proportion (95% CI) 0.94 (0.83, 0.98)
Number of relapses, n (%)
0 52 (95%) 52 (95%)
1 3 (5%) 2 (4%)
2 0 (0%) 1 (2%)
Secondary endpoints
Mean time to first-GADþ lesion (95% CI),
in monthsa
10.9 (10.1, 11.7)
Mean time to 3-month sustained disability
worsening (95% CI), in monthsa
11.8 (11.4, 12.0)
Mean number of new or enlarging T2
lesions (95% CI)
0.42 (0.23, 0.77)
Number of new or enlarging T2 lesions,
n (%)
0 48 (87%) 42 (76%)
1 4 (7%) 9 (16%)
2 3 (5%) 4 (7%)
Exploratory endpoints
Annualized relapse rate (95% CI) 0.08 (0.02, 0.26)
Mean number of GADþ lesions (95% CI) 0.34 (0.18, 0.63)
Number of GADþ lesions, n (%)
0 47 (85%) 44 (80%)
1 5 (9%) 6 (11%)
2 3 (5%) 5 (9%)
Patients free of new or enlarging T2
lesions, n
42
Proportion (95% CI) 0.74 (0.60, 0.84)
Patients free of GADþ lesions, n 44
Proportion (95% CI) 0.78 (0.64, 0.87)
Patients free of 3-month sustained disability
worsening, n
53
Proportion (95% CI) 0.96 (0.85, 0.99)
Patients achieving NEDA-3,b n 39
Proportion (95% CI) 0.68 (0.53, 0.79)
Symbol digit modalities test
Mean (SE)c 53.2 (1.6) 52.9 (1.6)
Change from baseline (95% CI) 1.4 (–0.4, 3.1) P¼0.134 1.0 (–0.8, 2.8) P=0.254
Beck depression inventory-II
Mean (SE)† 7.0 (1.0) 8.3 (1.0)
Change from baseline (95% CI) –0.2 (–2.5, 2.0) P¼0.828 1.1 (–1.1, 3.4) P¼0.314
aRestricted mean with upper limit of 12 months estimated from Kaplan–Meier survival curve.
bNEDA-3 defined as no occurrence of clinical relapses, sustained worsening in EDSS, GADþ lesions, or new or
enlarging T2 lesions.
cLeast squares mean with standard error estimated from linear mixed model.
GADþ: gadolinium enhancing; CI: confidence interval; IQR: interquartile range; SE: standard error.
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(20.0%), and vertigo/balance difficulties/dizziness
(20.0%) (Table 3). Additional common side effects
of teriflunomide included elevated transaminases
(none greater than 3 upper limit of normal)
(14.6%), leukopenia (1.8%), and peripheral neurop-
athy (3.6%) (see Supplementary Table 1). There
were no cases of PML, other opportunistic infections
or deaths. Three patients discontinued teriflunomide
due to AEs, one due to diarrhea, one due to
leukopenia, abscessed tooth, and dental infection
after implant, and the patient with empyema, pleural
effusion, and moderate lymphopenia (Table 3).
Discussion
Strategies are needed for transitioning natalizumab-
treated, JCV-positive MS patients to other therapeu-
tic agents to mitigate PML risk, while reducing the
Figure 2. Survival analysis. Results indicate a high proportion of patients free from (a) relapse, (b) sustained disability
worsening, (c) new or enlarging T2 lesions, (d) new gadolinium-enhancing lesions, and (e) evidence of disease activity.
(f) Subgroup analyses indicate that patients with disease duration of less than 15 years are more likely to have new
gadolinium-enhancing (GADþ) lesions. For panels (a) to (e), solid lines denote Kaplan–Meier estimate and shaded areas
denote 95% confidence intervals.
Cohan et al.
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Table 3. Adverse events.
Mild–moderate
No. of patients (%)
Severe
No. of patients (%)
Serious adverse event
Brain abscess 0 (0) 1 (1.8)
Empyemaa 0 (0) 1 (1.8)
Gangrenous appendicitis, ruptured 0 (0) 1 (1.8)
Obstructive hydrocephalus 0 (0) 1 (1.8)
Pleural effusiona 0 (0) 1 (1.8)
Pneumonia 0 (0) 1 (1.8)
Pyelonephritis 1 (1.8) 0 (0)
Right pneumothorax 0 (0) 1 (1.8)
Squamous cell carcinoma, left ankle 0 (0) 1 (1.8)
Subfalcial herniation 0 (0) 1 (1.8)
Adverse events with five or more patients
Hair thinning/loss 20 (36.4) 0 (0)
Diarrheab/loose stool 17 (30.9) 1 (1.8)
Headache 12 (21.8) 0 (0)
Nausea/vomiting 11 (20.0) 0 (0)
Vertigo/balance difficulty/dizziness 11 (20.0) 0 (0)
Fatigue 10 (18.2) 0 (0)
Tingling/paresthesia 10 (18.2) 0 (0)
Upper respiratory infection 10 (18.2) 0 (0)
Cognitive changes 8 (14.6) 0 (0)
Elevated transaminases 8 (14.6) 0 (0)
Extremity joint pain 8 (14.6) 0 (0)
Other infections 8 (14.6) 0 (0)
Sensory decrease/disturbance 8 (14.6) 0 (0)
Urinary tract infection 8 (14.6) 0 (0)
Depression 7 (12.7) 1 (1.8)
Rashes/eczema 7 (12.7) 0 (0)
Abdominal pain/discomfort 6 (10.9) 0 (0)
Anxiety 6 (10.9) 0 (0)
Ophthalmic changes 6 (10.9) 0 (0)
Decreased appetite 5 (9.1) 0 (0)
Heartburn 5 (9.1) 0 (0)
Hypertension 5 (9.1) 0 (0)
Stiffness/spasticity 5 (9.1) 0 (0)
Migraine 3 (5.5) 2 (3.6)
Additional adverse events causing teriflunomide withdrawal
Abscessed tooth, left molarc 1 (1.8) 0 (0)
Dental infection secondary to implantc 1 (1.8) 0 (0)
Leukopeniac 1 (1.8) 0 (0)
Lymphopeniaa 1 (1.8) 0 (0)
Percentages are based on total number of enrolled patients (N¼55). All adverse events (N¼342) reported for those who
experienced adverse events as of the date the final patient completed the month 12 visit (N¼47). Relapse and pro-
gression of multiple sclerosis were not reported as adverse events, as these were categorized separately for reporting in
the main text.
aOne patient discontinued due to severe empyema, severe pleural effusion, and mild to moderate lymphopenia.
bOne patient discontinued due to severe diarrhea.
cOne patient discontinued due to mild to moderate leukopenia, abscessed tooth and dental infection.
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risk of MS activity recurrence. Based on pharmaco-
dynamics, clinical and MRI data, natalizumab
retains therapeutic activity for 3 or more months
after the last dose,17,25 leading some clinicians to
employ post-natalizumab washout periods of 3 or
more months because of potential risks of substitut-
ing another DMT while natalizumab is still thera-
peutically active. However, the return of MS
disease activity may correlate with longer post-
natalizumab washout durations.7,8,15,18 Analyses of
immune cell populations during natalizumab therapy
suggest potential mechanisms to explain the timing
of returned, and in some cases heightened, MS dis-
ease activity following natalizumab discontinuation.
Sustained natalizumab treatment was associated with
increased circulating T cells, B cells and mono-
cytes,26–30 possibly from impaired cell migration
into the CNS, and elevated mobilization of T and
B cell stem cells.31 Return to baseline lymphocyte
levels and subtherapeutic alpha 4 integrin saturation
required up to 16 weeks after the last natalizumab
dose.32 Natalizumab-treated patients had upregula-
tion of interleukin (IL)-17 and IL-22-producing
CD4þ and CD8þ T cells,27,29 preferential transmi-
gration of T-helper 17 cells into the CNS,33 upregu-
lation of IL-17 receptors on endothelial cells,33
increased mRNA expression and circulating levels
of pro-inflammatory cytokines.27 These changes
may set the stage for elevated disease activity fol-
lowing natalizumab discontinuation.
The introduction of a new DMT can be guided by
the timing of the therapeutic onset of that DMT
before the efficacy of natalizumab ceases, which is
estimated to be approximately 16 weeks.32
Pharmacodynamic studies of teriflunomide have
demonstrated therapeutic effects on MRI activity
and relapses within 6 weeks of its initiation.34 This
largely informed our strategy to eliminate natalizu-
mab washout and introduce teriflunomide at the time
patients would have received their next natalizumab
infusion. Although there may be concern for the
risks of adding a second DMT while natalizumab
is still biologically active, only one reported patient
developed PML after 3 months of teriflunomide and
8 months after discontinuing natalizumab.35 To our
knowledge, there are no reports of the risk of other
opportunistic infections.
To increase our ability to detect disease reactivation,
we obtained monthly brain MRIs for the first
6 months, a time interval that has a high risk of
post-natalizumab relapse.6–11 Initiating terifluno-
mide at the time patients were due for their next
natalizumab infusion was associated with low
12-month relapse risk (proportion of relapse-free
patients 0.94), and only two patients (4%) experi-
enced SDW, in contrast to some post-natalizumab
outcomes previously reported.6–9,12,13 While direct
comparisons to other reported studies of post-
natalizumab DMT cannot be made, the low risks of
relapse and SDW we observed may provide potential
guidelines for transitioning patients off natalizumab.
Although 15% of our patients had gadolinium-
enhancing scans within the first 6 months, most of
these would have gone undetected if the common
practice of MRI scanning 6–12 months after changing
therapy had been followed. The safety and side-effect
profile in our study was similar to those of larger
teriflunomide controlled clinical trials,15,16, further
supporting no increased risk from initiating terifluno-
mide without natalizumab washout.
The potential shortcomings of this study include its
open label design, the absence of a comparator
DMT, and the small number of subjects. The pro-
portion of relapse-free patients (94%) is higher than
the approximately 76% reported in the pivotal teri-
flunomide clinical trials,21,22 but may reflect our
smaller cohort size and only 12 months of observa-
tion, and may increase as we extend the study dura-
tion to 24 months. Excluding patients with
enhancing MRI lesions at screening may introduce
selection bias, which would not be likely to occur in
routine clinical practice and did not occur in the
teriflunomide placebo controlled trials.21,22 No
cases of PML or other opportunistic infections
were observed, which may be related to the small
cohort and only one year of observation, but is con-
sistent with the sole report of PML in a patient being
treated with teriflunomide.35 This study was not
designed to examine the comparative efficacy and
safety of other DMTs, nor were clinical neurologists
or the patients blinded to the treatment employed.
The strengths of this study include high frequency,
rigorous attention to consistency and quality of MRI
scanning, and the reading of all MRIs by pre-
designated neuroradiology MS experts. All patients
at each site were studied on the same 3T scanner
throughout the study. Each patient was clinically
assessed at every visit by the same neurologist,
who had extensive experience in MS patient care,
evaluation and clinical research, using prespecified
criteria for relapses and disability progression.
Our results suggest that teriflunomide use without
washout is a potentially effective therapy for stable
Cohan et al.
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patients being taken off natalizumab, with a low risk
of post-natalizumab relapses and an acceptable
safety profile. This is the first prospective study of
teriflunomide that addresses the issue of recurrent or
increased MS disease activity following natalizumab
withdrawal. These results may prompt further inves-
tigation of ‘no washout’ strategies with other DMTs
in the post-natalizumab setting.
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